Proteomics and Metabolomics in Drug Discovery
- 1st Edition, Volume 155 - January 1, 2027
- Latest edition
- Editor: Rossen Donev
- Language: English
Proteomics and Metabolomics in Drug Discovery explores how large-scale protein and metabolite analysis is transforming the identification, validation, and development of new therap… Read more
Description
Description
Proteomics and Metabolomics in Drug Discovery explores how large-scale protein and metabolite analysis is transforming the identification, validation, and development of new therapeutic targets. The book highlights emerging technologies, analytical strategies, and real-world applications that support biomarker discovery, mechanism-of-action studies, and precision medicine approaches in modern drug development.
Key features
Key features
- Covers the role of proteomics and metabolomics in modern drug discovery and development
- Explores biomarker identification, target validation, and mechanism-of-action studies
- Highlights cutting-edge analytical technologies, including mass spectrometry and bioinformatics tools
Readership
Readership
Academic researchers, Pharmaceutical and biotechnology scientists, R&D teams in pharma, biotech, and CROs
Table of contents
Table of contents
1. Proteomics in Drug Discovery: From Biomarker Identification to Targeted Therapeutics
Ajaz Ahmad Bhat
2. Integrative Proteo-Metabolomic Platforms in Drug Discovery: Technologies, Biomarker Signatures, and Translational Opportunities
Dilpreet Singh
3. Integrating Proteomics and Metabolomics in Drug Discovery: Unveiling Molecular Mechanisms and Therapeutic Potential
Muzafar Ahmad Ahmad Macha, Ajaz Ahmad Bhat, Ibrah Bashir and Geetanjali Sageena
4. Functional Omics for Disease Modeling and Target Identification in Neurodegenerative Drug Discovery
Bhupendra Goplabhai Prajapati and Sourav Ghosh
5. Proteo-Metabolomic Approaches in CNS Drug Discovery: New Avenues for Psychiatric Disorders
Bhupendra Goplabhai Prajapati
6. The drug discovery landscape of Alzheimer’s disease
Subashchandrabose Chinnathambi and Liya Prakash
7. Protein degradation pathways in Parkinsons disease
Subashchandrabose Chinnathambi
8. Tau and Amyloid- β imaging with proteomics and genomics
Subashchandrabose Chinnathambi
9. Chemokine receptor CX3CR1 interacts with Tau and regulates its microglial activity in Alzheimer's disease
Subashchandrabose Chinnathambi
10. Large scale proteome and metabolomic analysis in neurodegenerative diseases
Subashchandrabose Chinnathambi
11. Cellular and Molecular Consequences of Tau and Amyloid- in Alzheimers disease
Subashchandrabose Chinnathambi, Gowshika Velmurugan, Riddhi Bharatkumar Upadhyay and Murugan Sevanan
12. Mechanistic Landscape of Anticancer Peptides/ Proteins: Insights from cell lines and animal models
Ajaz Ahmad Bhat
13. The Spatial Multi-Omics Revolution in Drug Discovery: Integrating Proteomics and Metabolomics for Precision Target Mapping and Mechanistic Therapeutics
Selvaraj Chandrabose Sr.
14. Targeting Lipid Metabolism through Phytochemicals: Systems Biology and In Silico Perspectives
Amit Joshi and Jharna Maiti
15. Metabolomic strategies in drug discovery
Daniela Aparecida Chagas de Paula
16. Integrative In Silico Proteomics and Metabolomics Analysis for Target Identification and Drug Repurposing
George Priya Doss C
17. Proteome and Secretome Profiling of Wild-Type Salmonella Typhimurium for Expression-Guided Drug Target Prioritization
George Priya Doss C
18. Utilization of proteomic technologies in pharmaceutical research for the identification and validation of molecular biomarkers
George Priya Doss C
19. A Framework for Implementing Industrial Mass Spectrometry Protocols in Peptide Research
Akhilesh Kumar Kuril
Ajaz Ahmad Bhat
2. Integrative Proteo-Metabolomic Platforms in Drug Discovery: Technologies, Biomarker Signatures, and Translational Opportunities
Dilpreet Singh
3. Integrating Proteomics and Metabolomics in Drug Discovery: Unveiling Molecular Mechanisms and Therapeutic Potential
Muzafar Ahmad Ahmad Macha, Ajaz Ahmad Bhat, Ibrah Bashir and Geetanjali Sageena
4. Functional Omics for Disease Modeling and Target Identification in Neurodegenerative Drug Discovery
Bhupendra Goplabhai Prajapati and Sourav Ghosh
5. Proteo-Metabolomic Approaches in CNS Drug Discovery: New Avenues for Psychiatric Disorders
Bhupendra Goplabhai Prajapati
6. The drug discovery landscape of Alzheimer’s disease
Subashchandrabose Chinnathambi and Liya Prakash
7. Protein degradation pathways in Parkinsons disease
Subashchandrabose Chinnathambi
8. Tau and Amyloid- β imaging with proteomics and genomics
Subashchandrabose Chinnathambi
9. Chemokine receptor CX3CR1 interacts with Tau and regulates its microglial activity in Alzheimer's disease
Subashchandrabose Chinnathambi
10. Large scale proteome and metabolomic analysis in neurodegenerative diseases
Subashchandrabose Chinnathambi
11. Cellular and Molecular Consequences of Tau and Amyloid- in Alzheimers disease
Subashchandrabose Chinnathambi, Gowshika Velmurugan, Riddhi Bharatkumar Upadhyay and Murugan Sevanan
12. Mechanistic Landscape of Anticancer Peptides/ Proteins: Insights from cell lines and animal models
Ajaz Ahmad Bhat
13. The Spatial Multi-Omics Revolution in Drug Discovery: Integrating Proteomics and Metabolomics for Precision Target Mapping and Mechanistic Therapeutics
Selvaraj Chandrabose Sr.
14. Targeting Lipid Metabolism through Phytochemicals: Systems Biology and In Silico Perspectives
Amit Joshi and Jharna Maiti
15. Metabolomic strategies in drug discovery
Daniela Aparecida Chagas de Paula
16. Integrative In Silico Proteomics and Metabolomics Analysis for Target Identification and Drug Repurposing
George Priya Doss C
17. Proteome and Secretome Profiling of Wild-Type Salmonella Typhimurium for Expression-Guided Drug Target Prioritization
George Priya Doss C
18. Utilization of proteomic technologies in pharmaceutical research for the identification and validation of molecular biomarkers
George Priya Doss C
19. A Framework for Implementing Industrial Mass Spectrometry Protocols in Peptide Research
Akhilesh Kumar Kuril
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 155
- Published: January 1, 2027
- Language: English
About the editor
About the editor
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UK